Improved efficacy of concurrent anti-PD1 antibody plus AVD versus ABVD in patients with newly diagnosed early unfavorable and advanced stage classic Hodgkin lymphoma: a retrospective matched cohort study
In this real-world study, concurrent anti-PD1 antibody with AVD showed significantly prolonged modified PFS and improved CR rate after cycle 2 versus ABVD regimen, supporting the use of novel agents in frontline therapy.
Authors
- Peng Sun (ORCID: https://orcid.org/0000-0003-3811-0371)
- Qingqing Cai (ORCID: https://orcid.org/0000-0001-9875-2419)
- Mengqiu Wu (ORCID: https://orcid.org/0000-0001-9488-5572)
- Zhiming Li (ORCID: https://orcid.org/0000-0002-8170-5621)
- Zhongjun Xia
- Baitian Zhao
- Panpan Liu (ORCID: https://orcid.org/0000-0002-7447-7026)
- Yu Wang (ORCID: https://orcid.org/0000-0002-5394-0050)
- He Huang (ORCID: https://orcid.org/0000-0003-0637-8015)
- Huiqiang Huang (ORCID: https://orcid.org/0000-0002-9090-1907)
- Hang Yang
- Yi Xia (ORCID: https://orcid.org/0000-0002-2838-2552)
- Man Nie
Institutions
- Sun Yat-sen University (CN)
- Sun Yat-sen University Cancer Center (CN)
Publication Details
- Journal
- Cancer Immunology Immunotherapy
- Published
- 2025-05-15
- DOI
- https://doi.org/10.1007/s00262-025-04041-z
- Citations
- 2
- Primary Topic
- Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 2.94
Funders
- Sun Yat-sen University
- Guangzhou Science and Technology Program key projects
- Sun Yat-sen University Cancer Center
- Basic and Applied Basic Research Foundation of Guangdong Province